Los Angeles, CANCT06162884Now EnrollingIRB Ready

Pulmonary Fibrosis Clinical Trial in Los Angeles, CA

Access cutting-edge pulmonary fibrosis treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by University of California, Los Angeles

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access pulmonary fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pulmonary fibrosis treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this pulmonary fibrosis clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Pulmonary Fibrosis Study in Los Angeles

This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD). The purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc/ machine learning (AI/ML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-term predictive worsening.

Sponsor: University of California, Los Angeles

Who Can Participate

Inclusion Criteria

Established a diagnosis (within 5 years) of IPF by enrolling center as defined by ATS/ERS/JRS/ALAT criteria
Age over or equal to 40 years old
No history of lung transplant
FVC % predicted \>= 45%
DLCO % predicted \>=25%
Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OCs) also have to use one barrier method. Non-IPF ILD Inclusion Criteria:
Established a diagnosis (within 5 years) of non-IPF ILD by enrolling center.
Age over or equal to 18 years old
Presence of chronic fibrosis ILD defined as architectural distortions with reticulation and the presence of traction bronchiectasis by visual assessment: (1) estimating visually \>5% in whole lung, or (2) mild pulmonary fibrosis and \<5% in whole lung (i.e., early non-IPF-ILD identified by a pulmonologist).
Patients treated with immunosuppressive agents (other than corticosteroids) for an underlying systemic disease need to be on a stable treatment for at least 12 weeks prior to screening
FVC % predicted \>= 45%
DLCO % predicted \>=25%
Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OCs) also have to use one barrier method

Exclusion Criteria

Planned to participate in an intervention trial within the next 6 months
Currently listed for lung transplantation at the time of enrollment
Malignancy, treated or untreated, other than malignancy unlikely to affect prognosis in the next 3 years such as skin cancer or non-metastatic prostate cancer within the past 5 years
Any clinically significant co-morbidity, which in the view of investigator, is likely to contribute to mortality or ability to perform PFT's in the next 2 years
Prebronchodilator Forced Expiratory Volume in 1 second (FEV1)/Forced vital capacity (FVC) \<0.7 at as screening
lung transplant after baseline or death
withdraw of consent or transition to another care center

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06162884) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Fibrosis Treatment Options in Los Angeles, CA

If you're searching for pulmonary fibrosis treatment options in Los Angeles, CA, this clinical trial (NCT06162884) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pulmonary fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary fibrosis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Fibrosis Trials in Los Angeles, CA

See all pulmonary fibrosis clinical trials recruiting in Los Angeles — not just this study.

Browse Pulmonary Fibrosis Trials in Los Angeles →

Browse More Trials by Condition

Pulmonary Fibrosis TrialsFibromyalgia TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA